SCYNEXIS (SCYX) Cash Funds Calculated per Share

Symbol and logo of brand SCYNEXIS Inc (SCYX)

The cash per share dynamics demonstrate the financial stability of SCYNEXIS, Inc. (SCYX), with the parameter stabilizing at 4.73. Business growth is driving collaboration with GSK on innovative antimycotics. High barriers to entry are ensured by Brexafemme patents and strict FDA oversight. Development stability is guaranteed by a cohesive staff of R&D specialists successfully working on new medical projects.

scynexis.com (SCYX) Cash per Share: for the period 07/04/2022 - 11/20/2026

Analytical breakdowns for SCYNEXIS, Inc.

- current price and projected stock value:
- cash and cash flow data:
Summary company analysis:SCYX (Scynexis)
Original product of scynexis.com

Regular licensing royalties from the strategic partnership provide SCYNEXIS, Inc. (SCYX) with a stable inflow of liquidity. By analyzing changes in cash per share, an investor can determine the portion of free cash flow attributable to a single security. This metric is calculated by dividing the total cash balance by the number of shares outstanding. While a high ratio ensures financial stability, it may signal underinvestment in the pipeline. This serves as a key indicator of the asset's solvency.